Skip to main content

Table 2 Baseline characteristics of RA

From: Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

Baseline characteristic Naïve group (n = 25) Switch group (n = 11) P
Disease duration (years) 13.2 ± 2.0 15.5 ± 2.7 n.s
Steinbrocker
 Stage (I/II/III/IV) 1/2/4/18 0/2/1/7 n.s
 Class (1/2/3/4) 2/8/15/0 0/3/8/0 n.s
 RF positive (%) 68.0 72.7 n.s
 ACPA positive (%) 72.0 81.8 n.s
 DAS28-ESR 3.60 ± 0.17 4.15 ± 0.32 n.s
 SDAI 6.90 ± 1.00 9.93 ± 1.38 n.s
 MTX (%) 60.0 45.5 n.s
 MTX dose (mg/week) 8.1 ± 0.9 7.2 ± 1.4 n.s
 PSL (%) 32.0 54.5 n.s
 PSL dose (mg/day) 5.3 ± 1.8 3.2 ± 0.6 n.s
 bDMARDs (%) 32.0 54.5 n.s
 bDMARDs IFX 2, ADA 1, TCZ 3, GLM 1, ABT 1 ETN 2, TCZ 1, GLM 2, ABT 1  
 csDMARDs (%) 36.0 27.3 n.s
  1. Data are presented as means ± standard deviation (SD), RA: rheumatoid arthritis; Naïve group: treatment-naïve group; Switch group: transitioning from bisphosphonate group; ACPA: anti-cyclic citrullinated peptide antibody; RF: rheumatoid factor; DAS: disease activity score; SDAI: simplified disease activity score; MTX: methotrexate; PSL: prednisolone; bDMARDs: biological disease-modifying anti-rheumatic drugs; csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs (salazosulfapyridine, iguratimod, bucillamine, tacrolimus); TCZ: tocilizumab; ETN: etanercept; ADA: adalimumab; ABT: abatacept
  2. P values from Mann-Whitney U tests for continuous variables and Chi-squared tests or Fisher’s exact tests for dichotomous variables